Ostock C, Lindenbach D, Goldenberg A, Kampton E, Bishop C (2014) Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Behav Brain Res 270:75-85. doi: 10.1016/j.bbr.2014.05.009

Summary: Dopamine loss is central to Parkinson’s disease and is often accompanied by noradrenergic denervation of the locus coeruleus. In this work the authors examined the role this loss plays in L-DOPA therapy using a rat Parkinson’s disease model. The rats received 10 μg of anti-DBH-SAP (Cat. #IT-03) into the left lateral ventricle. Loss of norepinephrine (NE) neurons did not affect behavior, but lesioned animals were less responsive to the pro-motor therapeutic effects of L-DOPA.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Shin E, Rogers J, Devoto P, Björklund A, Carta M (2014) Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Exp Neurol 257:25-38. doi: 10.1016/j.expneurol.2014.04.011

Summary: Although Parkinson’s disease is usually associated with loss of dopaminergic neurons in the substantia nigra, post-mortem studies have shown that noradrenergic neurons in the locus coeruleus also degenerate. In this work the authors develop a new Parkinson’s disease model by double lesioning with both 6-OHDA into the striatum and 2.5 μg bilateral injections of anti-DBH-SAP (Cat. #IT-03) into the lateral ventricles of rats. Double-lesioned animals performed worse on tests evaluating Parkinson’s disease symptoms than those lesioned only with 6-OHDA. The data suggest that Parkinson’s disease symptoms reflect the loss of both dopaminergic and noradrenergic neurons in the midbrain.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Shin EJ, Rogers, J, Björklund A, Carta M (2013) The effect of noradrenaline depletion on motor impairment and dopamine cell loss in a rat model of Parkinson’s disease. Neuroscience 2013 Abstracts 623.12. Society for Neuroscience, San Diego, CA.

Summary: Objective: Parkinson’s disease (PD) has been mainly known as a neurodegenerative disease with loss of dopaminergic (DA) neurons in the substantia nigra. However, studies of post mortem PD brains have shown that not only DA neurons but also the noradrenergic (NA) neurons in the locus coeruleus degenerate, and that the NA neurodegeneration may be as profound, and also precedes degeneration of the midbrain DA neurons. The early involvement of the NA system is also in line with the caudal-to-rostral disease progression predicted by the model proposed by Braak et al. Hence, we have investigated the effect of NA depletion on motor deficits and DA cell loss in a rat PD model. Methods: To generate two lesion paradigms, rats were injected with a dopamine toxin, 6-OHDA in striatum and/or a NA toxin, DBH-saporin in lateral ventricles. Animals have been tested in a battery of behavioural tests to check the degree of motor impairment. Perfused tissues were then subjected to immunohistochemistry to assess the amount of degeneration in striatal DA fiber and nigral DA neurons. Results: In three motor tests (cylinder, amphetamine-induced rotation, and corridor tests) there was no significant difference in motor deficit between groups. However, the DA- and NA-lesioned animals showed more severe motor deficits than the DA-lesioned animals in stepping, staircase, and rotarod tests. Post mortem analysis revealed that NA depletion did not affect the degree of DA loss in striatum and substantia nigra determined by optical densitometry with tyrosine hydroxylase staining and stereological cell estimation with vesicular monoamine transporter staining, respectively. These results suggest that Parkinsonian-like motor symptoms could be worsened by NA degeneration but it is not due to more profound DA cell degeneration upon NA removal but maybe by dysregulated DA cell function.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Kucinski A, Paolone G, Bradshaw M, Albin RL, Sarter M (2013) Modeling fall propensity in Parkinson’s disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci 33(42):16522-16539. doi: 10.1523/JNEUROSCI.2545-13.2013

Summary: Parkinson’s disease produces a range of symptoms, some of which are unresponsive to therapies such as levodopa. These nonmotor symptoms include cognitive impairments and deficiencies in gait and balance. Here the authors develop a system to assess fall propensity in rats and examine the interaction between loss of cortical cholinergic and striatal dopaminergic afferents. Rats received 160-ng injections of 192-IgG-SAP (Cat. #IT-01) into the nucleus basalis and substantia innominata of the basal forebrain. The results indicate that the dual lesions result in diminished striatal control of complex movement.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Ostock CY, Lindenbach D, Jaunarajs KL, Dupre KB, Goldenberg A, Bhide NS, Bishop C (2012) Noradrenergic denervation by DBH saporin reduces behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Neuroscience 2012 Abstracts 758.06. Society for Neuroscience, New Orleans, LA.

Summary: Dopamine (DA) replacement therapy with L-DOPA remains the most effective treatment for Parkinson’s disease (PD), but prolonged use frequently leads to deleterious side effects including involuntary choreic and dystonic movements known as L-DOPA induced dyskinesias (LID). It has been well established that DA loss in PD is accompanied by concomitant noradrenergic (NE) denervation of the locus coeruleus (LC); however, the contribution of NE loss to LID remains controversial and is often overlooked in traditional animal models of PD. Previous work from our lab demonstrated that rats with NE depletion induced by the selective NE neurotoxin DA beta hydroxylase saporin (DBH saporin) display reduced behavioral sensitivity to L-DOPA. The current investigation sought to further characterize the utility of DBH saporin lesions in a rodent model of PD by employing immunohistological techniques to correlate NE cell loss with behavioral outcome. Male Spraque-Dawley rats received unilateral 6-OHDA lesions of the medial forebrain bundle with intraventricular injections of either vehicle or DBH saporin. A number of well characterized behavioral tests were employed to determine lesion effects and L-DOPA responsiveness including: the abnormal involuntary movements scale for rodent dyskinesia, the forepaw adjusting steps (FAS) test as a metric of L-DOPA’s anti-parkinsonian efficacy, and locomotor chambers to observe motor performance. Sensitivity of primed animals to different doses of L-DOPA (0-12 mg/kg) and DA agonists SKF81297 (0., 0.08, 0.8 mg/kg) and Quinpirole (0, 0.05, 0.5 mg/kg) was assessed. Reduced behavioral responsiveness was associated with reductions in tyrosine hydroxylase positive cells within the LC of DBH saporin lesioned animals. Results indicate that NE denervation reduced anti-parkinsonian efficacy of L-DOPA on the FAS test. In primed rats, LC NE loss attenuated dyskinetic responses to L-DOPA and the DA agonist SKF81297. Taken together, these results indicate that DBH saporin lesions not only mimick the NE loss seen in idiopathic PD, but also reveal an underexplored contribution of the NE system to the manifestation of PD symptoms and LID.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Bhide NS, Dickinson S, Feinberg E, Mohamed M, Dupre K, Eskow-Jaunarajs K, Lindenbach D, Ostock C, Bishop C (2011) Norepinephrine denervation by dopamine beta-hydroxylase saporin impacts L-DOPA efficacy and side effects in a hemi-parkinsonian rat model. Neuroscience 2011 Abstracts 883.20. Society for Neuroscience, Washington, DC.

Summary: Dopaminergic neurodegeneration in Parkinson’s disease (PD) is accompanied by concomitant loss in the norepinephrine (NE) system. The exact contribution of NE denervation in the development of PD remains elusive. Recently, we demonstrated that NE neurons may contribute to the efficacy and side effects of L-DOPA, however, to better mimic NE loss observed in PD we employed the selective NE neurotoxin dopamine beta hydroxylase saporin (DHB saporin) and evaluated its effects on the anti-parkinsonian efficacy of L-DOPA and the development & expression of L-DOPA induced dyskinesia (LID). To do so, hemiparkinsonian adult Sprague-Dawley rats were exposed to intraventricular injections of either vehicle or DHB saporin. Three weeks later, animals were primed with L-DOPA (4mg/kg) for days 1-7 and L-DOPA (12 mg/kg) for days 9-15. During this period animals were monitored for motor-performance, a marker for L-DOPA’s anti-parkinsonian efficacy, and dyskinesia measured using Abnormal Involuntary Movements (AIMs) scale. Further, sensitivity of primed animals to different doses of L-DOPA (ranging from 2 to 12 mg/kg) was assessed. Results indicate that NE denervation resulted in reduced anti-parkinsonian efficacy of L-DOPA, but not the development of dyskinesia. In fully primed rats, NE denervation attenuated dyskinetic responses to L-DOPA when compared to animals with an intact NE innervation. These findings suggest that the NE system significantly modulates the anti-parkinsonian effects of L-DOPA and the expression of LID and indicate the importance of understanding the mechanisms by which NE modifies basal ganglia function in PD.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Spuz CA, Paolone G, Briscoe S, Bradshaw M, Albin RL, Sarter MF (2011) Deficits in attentional control of balance, mobility, and complex movements in a rat model of early state, multisystem Parkinson disease. Neuroscience 2011 Abstracts 244.02. Society for Neuroscience, Washington, DC.

Summary: In Parkinson disease (PD), basal forebrain cholinergic loss coincides with midbrain dopaminergic neuron loss and contributes to attentional deficits in PD. We hypothesize that these attentional deficits contribute to L-DOPA-insensitive impairments of mobility and postural control in PD. To assess complex movement control, we developed a novel Complex Motor Control Test (CMCT) for rats. The CMCT consists of several 2 m long beams (plank, 13.34 cm width; round rod, 3.81 cm diameter; square rod, 2.54 cm side length), which can be placed at zero, 22.5° or 45° angles in the vertical plane. Rods can rotate at 1 rpm or 10 rpm. A separate ladder apparatus (100 cm long, 7 cm wide, 2 cm between rungs, 5 mm rung diameter) can be placed at zero, 22.5° or 45° angles in the vertical plane and tilted laterally at 15° or 30° angles. Four high-resolution cameras and mirror system record animals’ performances. Rats are habituated by learning that plank traversal allows entry of home compartments containing individual bedding and palatable food. To separately assess attentional performance, we employed our Sustained Attention Task (SAT), including a distractor condition (dSAT). Our initial experiments determined CMCT and SAT performance in three groups: (1) animals with limited (40-60%) loss of cortical cholinergic afferents following immunotoxin 192-IgG saporin basal forebrain lesions (SAP); (2) animals with dopaminergic deafferentation following 6-OHDA dorsal striatal lesions (6-OHDA); (3) animals with both types of deafferentation (DUAL). SAT performance was dramatically impaired in SAP and DUAL animals. Control animals rapidly traversed angled and rotating rods and angled and tilted ladders. Deafferented animals were able to traverse the plank at all angles as effectively as control animals. Cholinergic lesions robustly impaired animals’ ability to maintain balance on the rods, to re-adjust posture on and traverse rotating rods, and had falls (into a net) or dismounts more frequently than control animals. These data reveal unexpectedly striking impairments in complex gait and movement control resulting from loss of corticopetal cholinergic neurons. These results support the hypothesis that basal forebrain cholinergic cell loss in PD contributes to complex posture and movement control deficits.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Szot P, Franklin A, White S, Raskind M (2010) Time- and dose-response of 6-hydroxydopamine on locus coeruleus noradrenegric neurons in c57bl/6 mice. Neuroscience 2010 Abstracts 157.20/R1. Society for Neuroscience, San Diego, CA.

Summary: Locus coeruleus (LC) noradrenergic neurons are severely reduced in Alzheimer’s and Parkinson’s disease. However, it is unclear why these neurons are lost and the consequence of this loss on the progression and symptoms of these neurodegenerative disorders. Therefore, establishing an animal model of LC noradrenergic neuronal loss is critical in determining how the LC contributes to these disorders. The purpose of this study was to determine the dose- and time-response of noradrenergic neurotoxicity of 6-hydroydopamine (6OHDA) in adult male C57BL/6 mice. Our laboratory recently demonstrated that DSP4 does not result in a loss of LC noradrenergic neurons. Neurotoxicity of 6OHDA on LC noradrenergic neurons was determined by measuring tyrosine hydroxylase (TH) mRNA expression and TH-immunoreactivity (IR) in LC noradrenergic neurons. TH mRNA was quantitated using MCID (OD), while TH-IR was used to determine if protein levels reflected what was observed with mRNA. 6OHDA (20 µg/µl bilaterally) and dopamine beta-hydroxylase-saporin (DBH-saporin; 1 µg/µl bilaterally) were initially administered into the lateral ventricles (icv) and sacrificed 2 weeks later. 6OHDA reduced TH mRNA and -IR in both the dopaminergic neurons of the substantia nigra (SNpc) and ventral tegmental nucleus (VTA), and LC by -46%, -65% and -63%, respectively. DBH-saporin icv injection did not affect dopaminergic or noradrenergic neurons. Injection of DBH-saporin into the LC (0.1 µg/µl unilaterally) also did not affect LC noradrenergic neurons 2 weeks later. As a time-course 6OHDA (7 µg/µl) was injected unilaterally into the LC (vehicle was administered in the alternate LC) and sacrificed 3 days, 2 and 3 weeks later. A loss of LC noradrenergic neurons was observed only 3 weeks later (-81.4%). 6OHDA was then injected unilaterally into the LC at 7, 10, and 14 ug/ul (vehicle was administered in the alternate LC) and sacrificed 2 weeks later. The 7 µg/µl dose of 6OHDA did not affect TH mRNA in the LC as compared to control side (-19%), 10 ug/ul 6OHDA significantly reduced TH mRNA in the LC by ~55%, and 14 ug/ul 6OHDA dramatically reduced TH mRNA in the LC by ~90%. TH-IR in the LC of the three different 6OHDA doses reflected closely the TH mRNA data. 6OHDA at the dose of 14 µg/µl, which resulted in a near complete loss of LC noradrenergic neurons, did not affect dopaminergic neurons in the SN (-9%) and VTA (+17%). These data indicate that DBH-saporin, at the parameters studied, did not affect mouse LC noradrenergic neurons. 6OHDA demonstrated a time- and dose-response reduction of mouse LC noradrenergic neurons. The consequence of this LC neuronal loss on forebrain noradrenergic markers will also be presented.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

King M, Jentsch JD (2007) Prefrontal cortical norepinephrine depletion does not impair spatial working memory in rats. Neuroscience 2007 Abstracts 645.16/CCC18. Society for Neuroscience, San Diego, CA.

Summary: The midbrain dopamine neurons are thought to encode a reward prediction error signal (Schultz et al., 1997; Bayer & Glimcher, 2005). Parkinson’s disease (PD) is characterized by a loss of nigral dopamine neurons. Dopaminergic drugs including the dopamine precursor L-Dopa and D2 receptor agonists are taken to relieve disease symptoms. We hypothesized that patients with moderate PD (1) show atypical reinforcement learning off dopaminergic medication due to dopamine neuron loss, and (2) show more normal reinforcement learning on dopaminergic drug therapy. We developed a method to rapidly assess reinforcement learning in human subjects (Rutledge et al., SfN 2005) adapted from matching law tasks used in monkeys (Sugrue et al., 2004; Lau & Glimcher, 2005). On each trial, subjects choose one of two animated crab traps. Rewards (crabs worth $0.10) were scheduled for the two targets with different independent rates. Scheduled rewards remained available until the associated target was chosen, as in the original matching law experiments (Herrnstein, 1961). After a 5-minute training period, subjects completed 800 trials as we varied reward probabilities across blocks. PD patients (n=19) completed one session on and one off dopaminergic medication. Age-matched controls (n=21) and healthy young subjects (n=20) completed one session. We found that young and elderly control subjects had similar reinforcement learning rates, but learning rates were reduced in PD patients (when tested off medication). Learning rates in the same PD patients were restored to control levels when dopaminergic drugs were administered. We also found that the reinforcement-independent strategies of our subjects were influenced by dopamine. Young subjects tended to alternate targets independent of reward history. In contrast, elderly subjects (who suffer some dopamine neuron loss) had a tendency to perseverate in their choices. This tendency was increased in PD patients (off medication), but restored to control levels when dopaminergic drugs were administered. This effect on choice is not explained by existing models of dopamine function. These data support a role for dopamine in human reinforcement learning. Future models of decision making in reinforcement learning tasks must also account for a reward-independent effect of dopamine on choice behavior.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Stead S, Trottier N, Doering LC (2005) Characterization of an immunotoxin model of Parkinson’s disease in mice. Neuroscience 2005 Abstracts 664.9. Society for Neuroscience, Washington, DC.

Summary: The primary event underlying the motor deficits of Parkinson’s disease (PD) is degeneration of neurons in the nigro-striatal system. The most widely employed laboratory rodent models of Parkinson’s are the neurotoxin 6-hydroxydopamine (6-OHDA) model that causes acute degeneration of the dopamine neurons in the substantia nigra (SN) and the MPTP mouse model. To date, there is no single model which accurately simulates the pathogenic, histological, biochemical and clinical features relevant for the investigation of PD. Toxins conveyed by axonal transport can be used to make selective lesions in the central nervous system. As previously shown in rats (Wiley et al., Cell. Mol. Biol., 2003), we have found that selective degeneration of the SN can be induced with an immunotoxin consisting of the highly active ribosome inactivating protein Saporin linked to an antibody to the dopamine transporter. A unilateral stereotaxic injection of anti-DAT-Saporin (0.25ug/2ul and 0.05ug/2ul) into the striatum of young (6-8 weeks old) female C57BL6 mice causes a progressive reduction in the number of DA neurons in the SN in comparison to the non-lesioned hemisphere and in various controls. Furthermore, in parallel to the immunohistochemical dopamine neuron death, the animals display a pronounced circling behaviour when challenged with apomorphine (3mg/kg). We are currently examining the affected brain sections for inclusion bodies and changes in astrocytes. This model exhibits the selective deterioration of the nigro-striatal system that occurs in Parkinson’s disease and provides a system to intervene at various stages of dopamine neuron loss and evaluate the effectiveness of stem cell therapy.

Related Products: Anti-DAT-SAP (Cat. #IT-25)